Loading…
Loading…
ODYY does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ODYY and 80,000+ other tickers.
See exactly how ODYY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ODYY and 80,000+ other tickers.
Odyssey Health, Inc. operates as a medical enterprise, primarily focused on the innovation and development of diverse healthcare products. Its current portfolio encompasses CardioMap, an advanced device for cardiac monitoring and screening, alongside the "Save A Life" line of devices engineered for choking emergencies. Additionally, the company is advancing neurosteroid drug compounds, PRV-001 and PRV-002, intended for the treatment of concussive injuries and various rare brain disorders. The organization, established in 2014 and headquartered in Las Vegas, Nevada, was previously known as Odyssey Group International, Inc.
Odyssey Health (OTCMKTS:ODYY - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Institutional and Insider Ownership 98.5% of Enovis shares are
Agreement Positions Company for Near-Term Revenue and Commercial Launch LAS VEGAS, April 22, 2026 /PRNewswire/ -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company focused on life-saving technologies, today announced the closing of a definitive sub-license agreement granting its wholly-owned subsidiary, Odyssey Medical Devices, Inc., exclusive worldwide marketing and distribution rights for BreastCheck™. This transaction positions Odyssey to enter the global breast cancer screening market, estimated at approximately $26 billion, with a differentiated, non-invasive, at-home screening solution.
Odyssey Health, Inc. (OTCMKTS:ODYY - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 63,696 shares, an increase of 15,065.7% from the January 15th total of 420 shares. Based on an average trading volume of 125,484 shares, the short-interest ratio
Service agreement and financing facility supports strategic growth and commercialization initiatives Service agreement and financing facility supports strategic growth and commercialization initiatives
Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck®